US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Regentis Biomaterials Ltd.

2.04

+0.04002.00%

Pre-market: 1.94-0.1000-4.90%04:00 EDT

Volume:24.47K

Turnover:50.33K

Market Cap:14.35M

PE:-0.08

High:2.14

Open:2.00

Low:2.00

Close:2.00

52wk High:15.50

52wk Low:1.23

Shares:7.04M

Float Shares:4.84M

Volume Ratio:1.32

T/O Rate:0.51%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-24.1591

EPS(LYR):-24.1600

ROE:--

ROA:-107.53%

PB:3.03

PE(LYR):-0.08

Loading ...

Overview Company News Filings

NYSE American New 52-Week Highs And Lows

Amex Halt Add Info Lst 2.730000

THOMSON REUTERS

Regentis Biomaterials enters collaboration with Humanitas Research Hospital

Regentis Biomaterials files Form 3 for Chief Medical Officer Galit Reske

Regentis Biomaterials Director Keith Valentine Files Initial Beneficial Ownership Statement

Regentis Biomaterials Ltd. CEO Ehud Geller files initial beneficial ownership statement

Regentis Biomaterials Director Susan Alpert filed initial beneficial ownership statement

Regentis Biomaterials Director Efraim Cohen-Arazi Files Initial Beneficial Ownership Statement

Regentis Biomaterials director Jeff Dykan files initial beneficial ownership statement

Regentis Biomaterials CFO Gon Ori files initial beneficial ownership statement

Regentis Biomaterials Ltd. files Form 3 as Chief Accounting Officer Arie Gordashnikov reports no beneficial ownership

Regentis Biomaterials Director Pini Ben-Elazar Files Initial Beneficial Ownership Statement

NYSE American New 52-Week Highs And Lows

Regentis Biomaterials initiated with a Buy at ThinkEquity

Regentis reports FY 2025 G&A expense USD 6.6 million, up 832.2%

Regentis reports FY 2025 operating expenses of USD 7.0 million

Regentis Biomaterials appoints Galit Reke as CMO

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/RGNT/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RGNT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RGNT\",,,,,undefined,":{"symbol":"RGNT","market":"US","secType":"STK","nameCN":"Regentis Biomaterials Ltd.","latestPrice":2.04,"timestamp":1788206400000,"preClose":2,"halted":0,"volume":24473,"hourTrading":{"tag":"盘前","latestPrice":1.94,"preClose":2.04,"latestTime":"04:00 EDT","volume":210,"amount":417.50001299999997,"timestamp":1788249608830,"change":-0.1,"changeRate":-0.04902,"amplitude":0},"delay":0,"changeRate":0.020000000000000018,"floatShares":4842164,"shares":7036500,"eps":-24.159056,"marketStatus":"Pre-Mkt","change":0.04,"latestTime":"09-01 05:20:06 EDT","open":2,"high":2.14,"low":2,"amount":50333.9935369,"amplitude":0.07,"askPrice":2.3,"askSize":100,"bidPrice":1.82,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-24.159056,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788269400000},"marketStatusCode":1,"adr":0,"listingDate":1764824400000,"exchange":"AMEX","adjPreClose":2.04,"preHourTrading":{"tag":"盘前","latestPrice":1.94,"preClose":2.04,"latestTime":"04:00 EDT","volume":210,"amount":417.50001299999997,"timestamp":1788249608830,"change":-0.1,"changeRate":-0.04902,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":2.0019,"preClose":2.04,"latestTime":"19:25 EDT","volume":745,"amount":1521.3585,"timestamp":1788218726005,"change":-0.0381,"changeRate":-0.018676,"amplitude":0.033382},"volumeRatio":1.3201929032598405},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RGNT\",,,,,undefined,":{"symbol":"RGNT","floatShares":4842164,"roa":"-107.53%","roe":"--","lyrEps":-24.159999,"volumeRatio":1.3201929032598405,"shares":7036500,"dividePrice":0,"high":2.14,"amplitude":0.07,"preClose":2,"low":2,"week52Low":1.2316,"pbRate":"3.03","week52High":15.5,"institutionHeld":0,"latestPrice":2.04,"eps":-24.159056,"divideRate":0,"volume":24473,"delay":0,"ttmEps":-24.159056,"open":2,"prevYearClose":6.74,"prevWeekClose":2,"prevMonthClose":2.04,"prevQuarterClose":3.53,"fiveDayClose":2.16,"twentyDayClose":1.87,"sixtyDayClose":1.72},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RGNT\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RGNT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RGNT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RGNT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RGNT","date":"2026-08-28","current":-0.08444,"percent":0.779487,"low":-9.624274,"twenty":-5.92034,"median":-1.201659,"eighty":-0.779867,"high":11.294138,"avg":-2.312046,"sd":3.502008,"marketCap":10669518},"quantilePoints":[{"date":"2025-09-12","current":11.294138,"twenty":11.294138,"median":11.294138,"eighty":11.294138,"marketCap":54223158},{"date":"2025-09-17","current":11.294138,"twenty":11.294138,"median":11.294138,"eighty":11.294138,"marketCap":54223158},{"date":"2025-11-14","current":-9.624274,"twenty":-1.256909,"median":11.294138,"eighty":11.294138,"marketCap":54223158},{"date":"2025-11-20","current":-9.624274,"twenty":-9.624274,"median":11.294138,"eighty":11.294138,"marketCap":54223158},{"date":"2025-11-26","current":-9.624274,"twenty":-9.624274,"median":-9.624274,"eighty":11.294138,"marketCap":54223158},{"date":"2025-12-05","current":-6.894806,"twenty":-9.624274,"median":-7.354459,"eighty":11.294138,"marketCap":38845335},{"date":"2025-12-12","current":-6.563855,"twenty":-9.624274,"median":-6.89021,"eighty":11.294138,"marketCap":36980758},{"date":"2025-12-19","current":-5.880074,"twenty":-9.624274,"median":-6.600627,"eighty":11.294138,"marketCap":33128337},{"date":"2025-12-26","current":-6.113394,"twenty":-9.624274,"median":-6.527083,"eighty":1.180569,"marketCap":34442863},{"date":"2026-01-02","current":-6.196132,"twenty":-8.716348,"median":-6.3708,"eighty":-5.580196,"marketCap":34909007},{"date":"2026-01-09","current":-6.352414,"twenty":-7.170598,"median":-6.31555,"eighty":-5.626198,"marketCap":35789501},{"date":"2026-01-16","current":-7.078667,"twenty":-7.005123,"median":-6.260483,"eighty":-5.72734,"marketCap":39881210},{"date":"2026-01-23","current":-6.664979,"twenty":-6.894806,"median":-6.333844,"eighty":-5.846096,"marketCap":37550490},{"date":"2026-01-30","current":-5.635354,"twenty":-6.892967,"median":-6.278869,"eighty":-5.846096,"marketCap":31749587},{"date":"2026-02-06","current":-4.421869,"twenty":-6.856195,"median":-6.196132,"eighty":-5.571003,"marketCap":24912808},{"date":"2026-02-13","current":-4.026566,"twenty":-6.723814,"median":-6.113762,"eighty":-5.331983,"marketCap":22685675},{"date":"2026-02-20","current":-3.594492,"twenty":-6.664979,"median":-6.113394,"eighty":-4.421869,"marketCap":20251367},{"date":"2026-02-27","current":-1.495219,"twenty":-6.600627,"median":-6.113394,"eighty":-4.026566,"marketCap":20406749},{"date":"2026-03-06","current":-1.271316,"twenty":-6.563855,"median":-6.053639,"eighty":-3.612878,"marketCap":17350916},{"date":"2026-03-13","current":-1.282663,"twenty":-6.527083,"median":-5.880074,"eighty":-1.504175,"marketCap":17505779},{"date":"2026-03-20","current":-1.196479,"twenty":-6.527083,"median":-5.644593,"eighty":-1.282663,"marketCap":16329542},{"date":"2026-03-27","current":-1.153672,"twenty":-6.526991,"median":-5.56181,"eighty":-1.271316,"marketCap":15745309},{"date":"2026-04-02","current":-1.138492,"twenty":-6.505001,"median":-5.341176,"eighty":-1.230216,"marketCap":15538134},{"date":"2026-04-10","current":-1.159364,"twenty":-6.396541,"median":-4.971155,"eighty":-1.194415,"marketCap":15822999},{"date":"2026-04-17","current":-1.214391,"twenty":-6.356091,"median":-4.421869,"eighty":-1.179477,"marketCap":16574009},{"date":"2026-04-24","current":-1.168851,"twenty":-6.34506,"median":-4.136653,"eighty":-1.176433,"marketCap":15952484},{"date":"2026-05-01","current":-1.104337,"twenty":-6.335719,"median":-3.755371,"eighty":-1.159364,"marketCap":15071989},{"date":"2026-05-08","current":-0.865254,"twenty":-6.326637,"median":-3.645054,"eighty":-1.156707,"marketCap":11808981},{"date":"2026-05-15","current":-0.777969,"twenty":-6.302772,"median":-3.401437,"eighty":-1.138492,"marketCap":10617724},{"date":"2026-05-22","current":-0.815919,"twenty":-6.267838,"median":-1.499697,"eighty":-1.134697,"marketCap":11135662},{"date":"2026-05-29","current":-0.751404,"twenty":-6.243936,"median":-1.282663,"eighty":-1.110409,"marketCap":10255168},{"date":"2026-06-05","current":-0.652735,"twenty":-6.210841,"median":-1.277843,"eighty":-0.952538,"marketCap":8908530},{"date":"2026-06-12","current":-0.721045,"twenty":-6.196132,"median":-1.273213,"eighty":-0.865254,"marketCap":9840818},{"date":"2026-06-18","current":-1.802612,"twenty":-6.163331,"median":-1.275111,"eighty":-0.865254,"marketCap":24602045},{"date":"2026-06-26","current":-1.574913,"twenty":-6.113836,"median":-1.282663,"eighty":-0.878916,"marketCap":21494418},{"date":"2026-07-02","current":-1.734302,"twenty":-6.113394,"median":-1.282663,"eighty":-0.902444,"marketCap":23669757},{"date":"2026-07-10","current":-1.38137,"twenty":-6.113394,"median":-1.369985,"eighty":-0.917624,"marketCap":18852935},{"date":"2026-07-17","current":-0.842484,"twenty":-6.113394,"median":-1.339625,"eighty":-0.916106,"marketCap":11498219},{"date":"2026-07-24","current":-0.74002,"twenty":-6.113394,"median":-1.282663,"eighty":-0.865254,"marketCap":10099787},{"date":"2026-07-31","current":-0.683095,"twenty":-6.113394,"median":-1.280253,"eighty":-0.838689,"marketCap":9322880},{"date":"2026-08-07","current":-0.747609,"twenty":-6.102271,"median":-1.275111,"eighty":-0.81535,"marketCap":10203374},{"date":"2026-08-14","current":-0.721045,"twenty":-6.085815,"median":-1.256325,"eighty":-0.781764,"marketCap":9840818},{"date":"2026-08-21","current":-0.781764,"twenty":-6.021463,"median":-1.222019,"eighty":-0.777969,"marketCap":10669518},{"date":"2026-08-28","current":-0.781764,"twenty":-5.92034,"median":-1.201659,"eighty":-0.779867,"marketCap":10669518}],"updateTime":1788226957131},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RGNT\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2632895949","title":"NYSE American New 52-Week Highs And Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2632895949","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632895949?lang=en_us&edition=fundamental","pubTime":"2026-05-04 22:21","pubTimestamp":1777904460,"startTime":"0","endTime":"0","summary":"COMPANY                      SYMBOL       HIGH         VOLUME. -------                      ------       ----         ------. abrdn EM ex-China Fd         AEF          9.31         20,598. Bancroft Fund                BCV         24.68          3,700. Ellsworth Growth & Incm      ECF         12.75         13,847. OptimumBank Holdings         OPHC         5.60          5,488. COMPANY                      SYMBOL       LOW          VOLUME. -------                      ------       ----         ------. CEL-SCI                      CVM          1.72        401,173. Regentis Biomaterials        RGNT         2.40          7,385. Copyright (c) 2026 Dow Jones & Company, Inc.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNT","NYSE","BK4107","BK4139","AFG","BK4117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629842971","title":"Amex Halt  Add Info Lst 2.730000","url":"https://stock-news.laohu8.com/highlight/detail?id=2629842971","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629842971?lang=en_us&edition=fundamental","pubTime":"2026-04-24 21:37","pubTimestamp":1777037838,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nAQN2LW0E5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627215368","title":"Regentis Biomaterials enters collaboration with Humanitas Research Hospital","url":"https://stock-news.laohu8.com/highlight/detail?id=2627215368","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627215368?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:51","pubTimestamp":1776343882,"startTime":"0","endTime":"0","summary":"Regentis Biomaterials (RGNT) announced a collaboration with Humanitas Research Hospital in Milan, Italy,. This collaboration is currently in the pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regentis-biomaterials-enters-collaboration-with-humanitas-research-hospital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regentis-biomaterials-enters-collaboration-with-humanitas-research-hospital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RGNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623324566","title":"Regentis Biomaterials files Form 3 for Chief Medical Officer Galit Reske","url":"https://stock-news.laohu8.com/highlight/detail?id=2623324566","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623324566?lang=en_us&edition=fundamental","pubTime":"2026-03-31 05:32","pubTimestamp":1774906347,"startTime":"0","endTime":"0","summary":"Regentis Biomaterials Chief Medical Officer Galit Reske reported holding employee stock options for 67,961 shares at a $4 exercise price in an initial beneficial ownership filing dated March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDLTbmpD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620779262","title":"Regentis Biomaterials Director Keith Valentine Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620779262","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620779262?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:32","pubTimestamp":1773865930,"startTime":"0","endTime":"0","summary":"Regentis Biomaterials reported an initial statement of beneficial ownership by director Keith Valentine. Keith Valentine disclosed an employee stock option for 37,500 shares of common stock. The option has an exercise price of USD 1.46 and an expiration date of Jan. 9, 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL9nb7C8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620262032","title":"Regentis Biomaterials Ltd. CEO Ehud Geller files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620262032","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620262032?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:32","pubTimestamp":1773865927,"startTime":"0","endTime":"0","summary":"Regentis Biomaterials reported an initial statement of beneficial ownership by Ehud Geller, a director and chief executive officer. The filing reported employee stock options covering 182,000 shares with an exercise price of USD 0.01. It also reported employee stock options covering 283,533 shares with an exercise price of USD 0.01. The filing reported warrants to purchase 92,821 shares with an exercise price of USD 5.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL6v6vCG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620262722","title":"Regentis Biomaterials Director Susan Alpert filed initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620262722","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620262722?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:32","pubTimestamp":1773865920,"startTime":"0","endTime":"0","summary":"Regentis Biomaterials reported an initial statement of beneficial ownership filed by Susan Alpert. Susan Alpert is listed as a director. The filing stated that Susan Alpert beneficially owned no securities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL5BWfJM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RGNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620262772","title":"Regentis Biomaterials Director Efraim Cohen-Arazi Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620262772","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620262772?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:31","pubTimestamp":1773865882,"startTime":"0","endTime":"0","summary":"Regentis Biomaterials filed an initial statement of beneficial ownership on behalf of Efraim Cohen-Arazi. He is listed as a director. The filing stated that no securities are beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL4HkFBl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RGNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620262701","title":"Regentis Biomaterials director Jeff Dykan files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620262701","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620262701?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:31","pubTimestamp":1773865881,"startTime":"0","endTime":"0","summary":"Jeff Dykan, a director of Regentis Biomaterials, filed an initial statement of beneficial ownership. The filing reported indirect beneficial ownership of 270,473 ordinary shares. It also reported indirect beneficial ownership of 130,465 ordinary shares. The filing listed warrants exercisable at USD 5 for 6,122 ordinary shares. It also listed warrants exercisable at USD 5 for 2,083 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL9Hp74n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RGNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620620862","title":"Regentis Biomaterials CFO Gon Ori files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620620862","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620620862?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:31","pubTimestamp":1773865880,"startTime":"0","endTime":"0","summary":"Regentis Biomaterials filed an initial statement of beneficial ownership naming Ori Gon as chief financial officer. The filing reported an employee stock option for 84,951 shares of common stock. The option exercise price was USD 4.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLbc2Ns2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620039262","title":"Regentis Biomaterials Ltd. files Form 3 as Chief Accounting Officer Arie Gordashnikov reports no beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2620039262","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620039262?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:31","pubTimestamp":1773865875,"startTime":"0","endTime":"0","summary":"Regentis Biomaterials filed an initial statement of beneficial ownership naming Arie Gordashnikov as Chief Accounting Officer. The filing reported that Gordashnikov beneficially owned no securities as of 03/18/2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL1yhpZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RGNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620262718","title":"Regentis Biomaterials Director Pini Ben-Elazar Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620262718","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620262718?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:30","pubTimestamp":1773865856,"startTime":"0","endTime":"0","summary":"Regentis Biomaterials reported that director Pini Ben-Elazar filed an initial statement of beneficial ownership. Ben-Elazar reported direct ownership of 128,666 ordinary shares. He also reported an employee stock option for 39,295 shares with an exercise price of USD 0.01. Ben-Elazar reported warrants for 15,831 shares with an exercise price of USD 5.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL5HK7wR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RGNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620607476","title":"NYSE American New 52-Week Highs And Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2620607476","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620607476?lang=en_us&edition=fundamental","pubTime":"2026-03-17 23:20","pubTimestamp":1773760800,"startTime":"0","endTime":"0","summary":"COMPANY                      SYMBOL       HIGH         VOLUME. -------                      ------       ----         ------. Imperial Oil                 IMO        125.44        209,995. COMPANY                      SYMBOL       LOW          VOLUME. -------                      ------       ----         ------. Credit Suisse Income Fnd     CIK          2.56         35,683. Green Circle Decarbonize     GCDT         1.80          9,147. NFT                          MI         0.5051        192,534. Nasus Pharma                 NSRX         2.70        278,185. Nuburu                       BURU       0.1756     10,216,696. Regentis Biomaterials        RGNT         3.00            810. Serina Therapeutics          SER          1.39         11,876. Copyright (c) 2026 Dow Jones & Company, Inc.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4139","BK4117","RGNT","BK4007","NYSE","AFG","BK4107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616336001","title":"Regentis Biomaterials initiated with a Buy at ThinkEquity","url":"https://stock-news.laohu8.com/highlight/detail?id=2616336001","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616336001?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:39","pubTimestamp":1772451591,"startTime":"0","endTime":"0","summary":"ThinkEquity initiated coverage of Regentis Biomaterials (RGNT) with a Buy rating and $10 price target Regentis is a single-asset medtech company ad...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regentis-biomaterials-initiated-with-a-buy-at-thinkequity-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regentis-biomaterials-initiated-with-a-buy-at-thinkequity-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RGNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614239737","title":"Regentis reports FY 2025 G&A expense USD 6.6 million, up 832.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614239737","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614239737?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:32","pubTimestamp":1771968770,"startTime":"0","endTime":"0","summary":"Regentis reported a FY 2025 net loss and comprehensive loss of USD 13.6 million, with an operating loss of USD 7.0 million and finance expense, net of USD 6.7 million. General and administrative expenses rose to USD 6.6 million , driven mainly by USD 5.4 million in non-cash share-based compensation tied to 2025 option grants and a special IPO-related bonus, while R&D expense was USD 331,000  following the completion of the Horizon 2020 grant funding in 2024. The company said it has not recognized any revenue to date and does not expect material revenue in the near term. Cash and cash equivalents were USD 7.4 million as of Dec. 31, 2025, and net cash used in operating activities was USD 1.4 million for FY 2025. Regentis said its cash is expected to fund operations through February 2027, and highlighted the Dec. 5, 2025 IPO of 1,250,000 ordinary shares at USD 8.00 per share for gross proceeds of about USD 10 million. On the business side, Regentis reiterated its focus on orthopedic tissu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL30m9wN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RGNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614372364","title":"Regentis reports FY 2025 operating expenses of USD 7.0 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614372364","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614372364?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:27","pubTimestamp":1771968472,"startTime":"0","endTime":"0","summary":"Regentis reported FY 2025 results, highlighting operating expenses of USD 7.0 million for the year ended Dec. 31, 2025, including USD 5.3 million in non-cash expenses. Cash and equivalents were USD 7.4 million as of Dec. 31, 2025; the company said this is expected to provide runway to complete site expansion and patient enrollment for its pivotal Phase III FDA trial of GelrinC in knee cartilage repair, with patient enrollment surpassing 50% and potential completion of recruitment and treatment by mid-2026. During the period, Regentis completed an IPO that closed on Dec. 5, 2025, raising gross proceeds of USD 10 million, and established 7 new U.S. clinical sites and 6 new European clinical sites. The company said GelrinC, already approved in Europe, is expected to be rolled out in clinics across Europe in 2026. Regentis also reported publication of GelrinC data in the journal Cartilage using MOCART MRI assessment, and said it received its 27th patent for the Gelrin platform technology, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL9vLHWw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612288759","title":"Regentis Biomaterials appoints Galit Reke as CMO","url":"https://stock-news.laohu8.com/highlight/detail?id=2612288759","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612288759?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:57","pubTimestamp":1771509458,"startTime":"0","endTime":"0","summary":"Regentis Biomaterials (RGNT) announced the appointment of Dr. Galit Reske as Chief Medical Officer. Dr. Reske brings extensive experience in clinic...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regentis-biomaterials-appoints-galit-reke-as-cmo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regentis-biomaterials-appoints-galit-reke-as-cmo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RGNT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":57,"code":"91000000","status":"200"}]}}